- West Virginia University WVU Cancer Institute
- WVU Cancer Institute Clinics
- Clinical Faculty
- West Virginia University WVU Cancer Institute
- Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program Clinical Service
- Clinical Faculty
- MBBS, St. John's Medical College
Original Peer-reviewed Publications:
1. Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Manag Res. 2017 Jul 12;9:307-314.
2. Morgan Belling, Abraham S. Kanate, Alexandra Shillingburg, et al. Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leukemia Research and Treatment. Volume 2017.
3. Anders B, Veltri L, Kanate AS, Shillingburg A, Shah N, Craig M, Cumpston A. Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia. Adv Hematol. 2017;2017:6464972.
4. Haverkos BM, Abbott D, Hamadani M, ..Kanate AS, et al. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 May 3.
5. Kanate AS, Hari PN, Pasquini MC, Visotcky A, et al. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Apr 12.
6. Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? Bone Marrow Transplant. 2017 Apr 3.
7. Ahn JS, Okal R, Vos JA, Smolkin M, Kanate AS, Rosado FG. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. J Clin Pathol. 2017 Mar
8. Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A. Treatment of severe mucositis pain with oral ketamine mouthwash. Support Care Cancer. 2017 Feb 11. doi: 10.1007/s00520-017-3627-6.
9. Hamadani M, Kanate AS, DiGilio A, Woo Ahn K, Smith SM, Wook Lee J, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK-Cell Leukemia. A CIBMTR Analysis. Biol Blood Marrow Transplant. 2017 Feb 1.
10. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematol Oncol. 2017 Jan 8. doi: 10.1002/hon.2380. [Epub ahead of print]
11. Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston A. Longterm outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.275. [Epub ahead of print]
12. Dhakal B, Veltri LW, Fenske TS, … Hari P, Kanate AS, Hamadani M. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus PlerixaforBased Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 Jun 21.
13. Snyder M, Shillingburg A, Newton M, Hamadani M, Kanate AS, Craig M, Cumpston A. Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. Support Care Cancer. 2016 May 2. [Epub ahead of print] PMID: 27137211
14. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016 Feb 18;127(7):938-47.
15. Lauren Veltri, Aaron Cumpston, Kanate AS. Hematopoietic Progenitor Cell Mobilization with “Just-in-Time” Plerixafor Approach is a Cost Effective Alternative to Routine Plerixafor Use. Cytotherapy. 2015 Dec;17(12):1785-92.
16. Satwani P, Ahn KW, Carreras J, Kanate AS et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015 Aug 3.
17. Rezvani AR, Kanate AS, Efron B, et al. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. Bone Marrow Transplant. 2015 Jul 6.
18. Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob Agents Chemother. 2015 Aug; 59(8):4424-8.
19. Bachanova V, Burns LJ, Ahn KW, Kanate AS, et al; for Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Impact of Pretransplantation 18Ffluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015 May 14.
20. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. Kanate AS, Pasquini MC, Hari PN, Hamadani M. World J Stem Cells. 2014 Apr 26;6(2):69-81.
21. Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS. Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Mar; 20(3):415-20.
22. Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. Ann Hematol. 2014 Apr; 93(4):677-82.
23. Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M. Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes.Biol Blood Marrow Transplant. 2013 Jul; 19(7):1133-5.
24. Kanate AS, Kharfan-Dabaja MA, Hamadani M. Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. Bone Marrow Res. 2012; 2012:897215. doi: 10.1155/2012/897215. Epub 2012 Oct 11.
25. Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2011 Fourth Quarter; 4(4):149-156.
26. Glance LE, Cumpston A, Kanate A, Remick S. Bendamustine-associated hemolytic anemia. Ann Pharmacother. 2009Nov, 43(11): 1903-6.
27. Saad A, Kanate A, Sehbai A, Marano G, Hobbs G, Abraham J. Correlation among [18F] fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer. Clinical Breast Cancer. 2008 Aug; 8(4):357-61.
28. Kanate AS, Auber ML, Higa GM. Priorities and uncertainties of administering chemotherapy in a pregnant woman with newly diagnosed colorectal cancer. J Oncol Pharm Pract. 2009 Mar; 15(1):5-8. Epub 2008 Aug 27.
Awards and Honors:
2016 WVU Medicine, Highest Performing, Exemplary Outcomes - Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS)
2016 WVU Medicine, Press Ganey Top Provider – Inpatient
2016 WVU Medicine, Press Ganey Top Provider – Outpatient
2015 Section of Hematology/Oncology “Faculty of the Year” Award.
2011 “Fellow of the Year” Award; Section of Hematology/Oncology, Dept. of Medicine, West Virginia University Morgantown, West Virginia
2010 American Society of Hematology Travel Grant.
2009 Physicians’ Educational Resource Travel Grant for American Society of Hematology Meeting, 2009.
2007 Member, West Virginia University medical jeopardy team at American College of Physicians state chapter.
Professional Organizations & Memberships:
2006 – Present American College of Physicians
2009 - Present American Society of Clinical Oncology
2009 - Present American Society of Hematology
2009 - Present American Society of Blood and Marrow Transplantation
2013 – Present West Virginia Oncology Society
About Abraham Kanate
Dr. Kanate received his Bachelor of Medicine; Bachelor of Surgery (MBBS) at St. John’s Medical College, Bangalore, India (1996-2002). He completed his Residency, in the Department of Internal Medicine, West Virginia University (2008) and Hematology/Oncology Fellowship (2011), at West Virginia University School of Medicine. Dr. Kanate went on to complete a Fellowship in Blood and Marrow Transplantation at Stanford University, Stanford Hospitals and Clinics, Stanford, California (2012).
Dr. Kanate came on board as an Assistant Professor in the Section of Hematology/Oncology as part of the Osborn Hematopoietic Malignancy and Transplantation Program at West Virginia University (2013-2018). In 2018, he was promoted to Associate Professor.
Dr. Kanate served as the Director of Myeloma and Lymphoma Service between 2014-2018. He took over as Medical Director of the Osborn Hematopoietic Malignancy and Cellular Therapy Program in July 2018.
Dr. Kanate is a member of the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, American Society of Blood and Marrow Transplantation and the West Virginia Oncology Society. He serves as a Working Group committee member for the Working Committees of the Center for International Blood and Marrow Transplantation Research (CIBMTR), Plasma Cell Disorders and Adult Solid Tumor Working Committee, Chronic Leukemia, as well as Graft versus Host Disease.
Dr. Kanate provides clinical and didactic teaching/lectures for medical students, residents, fellows, and pharmacy lectures to post-doctoral students. Dr. Kanate is actively involved with clinical research studies and clinical trials. Highlights include over 30 peer-reviewed publications and 35 oral and poster presentations at national/international meetings with over 400 citations, invited peer reviewer for Biology of Blood and Marrow Transplantation, Bone Marrow Transplant, and the American Journal of Hematology among others. He is an active participant in clinical trials for lymphoma, myeloma and stem cell transplantation. His special interests include lymphoma and myeloma. His research interests include T cell lymphoma, chronic leukemia, hematopoietic cell transplantation with special interest in supportive care and survivorship. Dr. Kanate has been the recipient of numerous teaching awards by the Department of Medicine (Highest Performing, Exemplary Outcomes – Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS), West Virginia University Medicine (Press Ganey Top Provider, Inpatient), West Virginia University Medicine (Press Ganey Top Provider, Outpatient), Section of Hematology/Oncology “Faculty of the Year” Award.
Grants and Research
“Personalizing chemotherapy for treatment of AML for patients in West Virginia” WVU-Marshall Health Grants Program Amount – 48,304.00 USD Year – 2016 Role – Co-Investigator
Patient Care Information
- Cancer / Oncology
- Hematology/Oncology (Cancer)
- Medical Oncology (Cancer)
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
- Hematology, American Board of Internal Medicine
Residency, Internal Medicine
West Virginia University
West Virginia University
Fellowship, Blood and Marrow Transplantation
Stanford University, Stanford Hospitals and Clinics